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Background. England is experiencing a rapid increase in invasive pneumococcal disease (IPD) caused by serotypes 8, 12F, and 
9N; their clinical characteristics and outcomes have not been described.
Methods. Public Health England conducts national IPD surveillance. Cases due to emerging serotypes were compared with 
those included in the 13-valent pneumococcal conjugate vaccine (PCV13) and the remaining non-PCV13 serotypes.
Results. There were 21 592 IPD cases during 2014–15 to 2017–18, including 20 108 (93.1%) with serotyped isolates and 17 450 
(86.8%) with completed questionnaires. PCV13 serotypes were responsible for 20.1% (n = 4033), while serotype 8 (3881/20 108 
[19.3%]), 12F (2365/20 108 [11.8%]), and 9N (1 296/20 108 [6.4%]) were together responsible for 37.5% of cases. Invasive pneu-
monia was the most common presentation (11 424/16 346 [69.9%]) and, overall, 67.0% (n = 11 033) had an underlying comorbidity. 
The median age (interquartile range) at IPD due to serotypes 8 (59 [45–72] years) and 12F (56 [41–70] years) was lower than sero-
type 9N (67 [53–80] years), PCV13 serotypes (68 [52–81] years), and remaining non-PCV13 serotypes (70 [53–82] years). Serotype 
9N IPD cases also had higher comorbidity prevalence (748/1087 [68.8%]) compared to serotype 8 (1901/3228 [58.9%]) or 12F 
(1042/1994 [52.3%]), and higher case fatality (212/1128 [18.8%]) compared to 8.6% (291/3365) or 10.0% (209/2086), respectively.
Conclusions. Serotypes 8 and 12F were more likely to cause IPD in younger, healthier individuals and less likely to be fatal, while 
serotype 9N affected older adults with comorbidities and had higher case fatality.
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Pneumococcal conjugate vaccines (PCVs) are highly effective in 
preventing invasive pneumococcal disease (IPD) caused by the 
respective vaccine serotypes [1, 2]. Countries with established 
childhood PCV programs have observed large declines in IPD 
caused by the vaccine serotypes across all age groups because of 
the direct and large indirect (herd) protection afforded by na-
tional immunization programs [3–9]. In the United Kingdom 
(UK), the 7-valent PCV (PCV7) was introduced into the na-
tional childhood immunization program at a 2 + 1 schedule in 
2006 and replaced with a 13-valent PCV (PCV13) without any 
catch-up in 2010. Both vaccines were associated with large and 
sustained declines in overall and vaccine-type IPD, although 
some increase in IPD due to nonvaccine serotypes was ob-
served following the introduction of each vaccine.
After reaching the lowest IPD incidence of 7.12 cases per 
100 000 in 2013–2014, England and Wales experienced a sudden 
and unexpected increase in IPD due to some non-PCV13 
serotypes, with an approximate doubling in incidence of non-
PCV13 IPD  from 4.20 per 100  000 during 2008–2010 to 7.97 
per 100 000 by 2016–2017 [3]. This increase was observed across 
all age groups, but especially in adults and older adults, with 3 
serotypes—8, 12F, and 9N—being responsible for approximately 
40% of all laboratory-confirmed IPD cases in England [3]. At the 
same time, IPD incidence due to some of the PCV13 serotypes 
plateaued instead of continuing to decline [3].
Little is known about the characteristics of IPD caused by 
the emerging serotypes. Here, we describe the age distribution, 
clinical presentation, underlying comorbidities, and outcomes 
of patients with IPD caused by the persisting PCV13 sero-
types, the 3 emerging serotypes, and the remaining non-PCV13 
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METHODS
IPD Surveillance
Public Health England (PHE) has been conducting national 
surveillance of IPD for > 3 decades. Hospital laboratories across 
England routinely refer invasive pneumococcal isolates to the 
PHE Respiratory and Vaccine Preventable Bacteria Reference 
Unit (RVPBRU) for confirmation and serotyping. The labora-
tories also routinely report all significant infections to PHE 
electronically through the Second-Generation Surveillance 
System. Reported IPD cases without submitted isolates to the 
PHE RVPBRU are actively followed up with the respective hos-
pital laboratory, thus ensuring both high case ascertainment 
and serotyping rates nationally.
Following the introduction of PCV7 into the childhood im-
munization program in September 2006, laboratory-confirmed 
IPD cases in vaccine-eligible children were followed up with 
their general practitioner (GP) using a postal questionnaire 
requesting information on vaccination history, clinical pre-
sentation, comorbidity status, complications, and outcomes 
at hospital discharge. Since 2014, IPD cases across all ages 
are followed up with the GP using standard postal question-
naires. Questionnaires that are not returned or are incomplete 
are actively followed up by reminder letters and telephone 
calls. Death status for IPD cases are confirmed through the 
Personal Demographics Service, an electronic national data-
base of National Health Service patient details, and those deaths 
occurring within 30 days of sample date are considered to be 
attributable to IPD.
Definitions
IPD was defined as isolation of Streptococcus pneumoniae 
from a normally sterile site, or detection of pneumococcal 
DNA by polymerase chain reaction (PCR) in cerebrospinal 
fluid (CSF) or pleural fluid. Meningitis was defined as iden-
tification of S.  pneumoniae (by culture/PCR) in the CSF or 
isolation of S. pneumoniae from the blood in a patient with 
clinical features of meningitis. Invasive pneumonia was de-
fined as identification of S.  pneumoniae (by culture/PCR) 
in pleural fluid or isolation of S.  pneumoniae in the blood 
in a patient with clinical features of pneumonia. Septicemia 
was defined as isolation of S.  pneumoniae from the blood 
without any discernible focus of infection. Patients with mul-
tiple clinical presentations were analyzed hierarchically as 
meningitis > pneumonia > other presentation > septicemia 
(without a focus of infection).
Comorbidity groups were based on clinical risk groups stated 
in the Immunisation Against Infectious Disease book popularly 
known as the “Green Book” [10] and included asplenia, chronic 
respiratory disease, chronic heart disease, chronic kidney di-
sease, diabetes, immunosuppression, cochlear implants, and 
CSF leaks. Comorbidity status was assessed by its presence 
or absence, the number of comorbidities for each patient, 
and whether the comorbidity was immunocompromising or 
nonimmunocompromising.
Data Management and Analyses
Laboratory and clinical data were regularly imported, matched, 
cleaned, and de-duplicated in Microsoft Access (Microsoft 
Corporation, Redmond, Washington) as part of national sur-
veillance. A  final dataset containing confirmed IPD cases 
during the 4 most recent epidemiological (July to June) years 
(2014–2015 to 2017–2018) was imported into Stata software 
version 15.1 (StataCorp LP, College Station, Texas) for analysis. 
Age was grouped into < 15, 15–44, 45–64, 65–79, and ≥ 80 years. 
The serotype groups were 8, 12F, 9N, PCV13 (subgrouped into 
serotype 3, serotype 19A, and the remaining PCV13 serotypes 
for some of the analyses), and the remaining non-PCV13/
nonemerging (remaining) serotypes.
Data that did not follow a normal distribution are presented as 
median with interquartile range and compared using the Mann-
Whitney U test; proportions were compared using the χ 2 or 
Fisher exact test, as appropriate. Multinomial logistic regression 
was used to assess independent risk factors associated with IPD 
clinical presentation after adjusting for surveillance year, and in-
cluding age group, serotype group (PCV13 serotypes, serotypes 8, 
9N, and 12F and remaining non-PCV13 serotypes), and comor-
bidity status. Multivariable logistic regression was used to identify 
any association between comorbidity status and serotype group 
after adjusting for surveillance year and age group. Independent 
risk factors for death were also assessed using a logistic regres-
sion model after adjusting for surveillance year, with comorbidity 
status, age group, and serotype group as in dependent variables.
RESULTS
There were 21  592 laboratory-confirmed IPD cases over the 
4-year surveillance period (2014–2015 to 2017–2018), in-
cluding 20  108 (93.1%) with serotyped isolates and 17  450 
(86.8%) with completed questionnaires; the characteristics of 
patients with returned questionnaires were similar to those 
with unreturned questionnaires, apart from a higher question-
naire completion rate for childhood cases (Table 1). IPD cases 
in all the serotype groups increased over the 4 surveillance 
years (Figure 1). PCV13 serotypes were responsible for 4033 of 
20 108 (20.1%) IPD cases with available serotype information, 
mainly due to serotypes 3 (1852/4033 [45.9%]), 19A (1110/4033 
[27.5%]), and 7F (433/4033 [10.7%]) which made up > 80% of 
PCV13-serotype IPD cases. Three emerging serotypes were re-
sponsible for 37.5% (7542/20 108) of IPD cases: 8 (3881/20 108 
[19.3%]), 12F (2365/20  108 [11.8%]), and 9N (1296/20  108 
[6.4%]). Fifty-five other serotypes were responsible for the re-
maining IPD cases (8533/20 108 [42.4%]), with a median of 39 
annual cases for each serotype. The characteristics of patients 
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The contribution of PCV13 serotypes to IPD increased with 
age from 25.7% (321/1247) in children aged < 15 years to 40.2% 
(1702/4229) in ≥ 80  year-olds (Table  2); however, only 5.5% 
(191/3492) of the PCV13-type IPD cases were in children. Of 
the emerging serotypes, the median age (interquartile range) at 
IPD due to serotype 8 (59 [45–72] years) and serotype 12F (56 
[41–70] years) was lower than serotype 9N (67 [53–80] years), 
PCV13 serotypes (68 [52–81] years) or the remaining serotypes 
(70 [53–82] years); consequently, a higher proportion of sero-
type 9N IPD cases (n = 294/1128 [26.1%]) were in ≥ 80 year-olds 
compared to cases due to serotypes 8 (n = 424/3365 [12.6%]) or 
12F (n = 270/2086 [12.9%]). On the other hand, the contribu-
tion of the remaining non-PCV13 serotypes to total IPD cases 
was higher in both children (740/1247 [59.3%]) and ≥ 80 year-
olds (2297/4229 [54.3%]) compared to an overall contribution 
of 42.3% (7379/17 450) across all age groups (Table 2). The main 
serotypes contributing to the remaining non-PCV13 serotypes 
were 22F (1218/7379 [16.5%]), 15A (758/7379 [10.3%]), and 
33F (632/7379 [8.6%]) (Supplementary Table 2).
Underlying Comorbidities
Overall, 11 033 of 16 726 (67.0%) cases with available informa-
tion had an underlying comorbidity, which increased with age 
from 30.1% (355/1180) in children to 82.9% (3392/4092) in 
≥ 80 year-olds, as did the number of underlying comorbidities, 
with 2.5% (30/1180) of children up to 22.9% (938/4092) of 
≥ 80 year-olds having ≥ 3 comorbidities. The most prevalent co-
morbidity was chronic lung disease which increased with age, 
followed by chronic heart disease (3848/16 237 [23.7%]) and im-
munosuppression/malignancy (3900/16 726 [23.3])  (Table 2).
Among the PCV13-serotype IPD cases, 65.5% (2188/3342) 
had an underlying comorbidity, including 68.2% (1067/1564) 
with serotype 3, 67.5% (615/911) with serotype 19A and 58.4% 
(506/867) with the remaining PCV13 serotypes. Among the 
emerging serotypes, those with serotype 9N IPD had a higher co-
morbidity prevalence (748/1087 [68.8%]) compared to both sero-
type 8 (1901/3228 [58.9%]) and serotype 12F (1042/1994 [52.3%]) 
(Table 3). Cases due to the remaining non-PCV13 serotypes had 
the highest comorbidity prevalence (5154/7075 [72.9%]).
Table 1. Characteristics of Patients With Confirmed Invasive 
Pneumococcal Disease in England Over a 4-Year Period (2014–2015 to 
2017–2018) With Questionnaires Completed by Their General Practitioners 




Age, y, median (IQR) 66 (49–67) 67 (53–80)
Age group, y, no. (%)   
 < 15 1247 (7.2) 21 (0.8)
 15–44 2377 (13.6) 382 (14.4)
 45–64 4728 (27.1) 773 (29.1)
 65–79 4869 (27.9) 810 (30.5)
 ≥ 80 4229 (24.2) 672 (25.3)
Sex, no. (%)   
 Male 8777 (50.3) 1397 (52.6)
 Female 8673 (49.7) 1261 (47.4)
Serotype groups, no. (%)   
 8 3365 (19.3) 516 (19.4)
 12F 2086 (12.0) 279 (10.5)
 9N 1128 (6.5) 168 (6.3)
 PCV13 serotypes 3492 (20.0) 541 (20.4)
 Remaining non-PCV13 serotypes 7379 (42.3) 1154 (43.4)
30-d case fatality rate, no. (%)   
 Yes 2895 (16.6%) 453 (17.0%)
 No 14 555 (83.4%) 2205 (83.0%)
Abbreviations: IQR, interquartile range; PCV13, 13-valent pneumococcal conjugate vaccine.
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Clinical Presentation
Pneumonia
Invasive pneumonia was the most common presentation, re-
sponsible for 69.9% (11  424/16  346) of cases with available 
clinical information. The proportion presenting with inva-
sive pneumonia increased with age, from 32.7% (393/1202) 
in children  <15 years to 79.2% (3195/4033) in ≥ 80  year-olds 
(Table 2). The responsible serotypes were 8 (n = 2516 [22.0%]), 
12F (n  =  1330 [11.6%]), 3 (n  =  1138 [10.0%]), 22F (n  =  830 
[7.3%]), and 9N (788 [6.9%]) (Supplementary Table 2). In chil-
dren, serotypes 12F (48 [12.2%]), 23B (39/393 [9.9%]), and 
15B/C (32 [8.1%]) were the 3 most prevalent serotypes. Among 
PCV13-serotype IPD cases, presentation with invasive pneu-
monia increased with age, reaching 83.0% (742/894) of cases 
in ≥ 80 year-olds, while presentation with meningitis and septi-
cemia declined with age (Supplementary Tables 1A–E). Among 
cases due to the remaining non-PCV13 serotypes, invasive 
pneumonia was less prevalent and other clinical presentations 
more prevalent than PCV13 serotype IPD cases (Table  3); in 
children, however, invasive pneumonia (250/715 [35.0%]) was 
the most common clinical presentation among the remaining 
non-PCV13 serotype IPD cases (Supplementary Table 2). In 
the multinomial logistic regression model, independent of 
surveillance year, age group, serotype group, and comorbidity 
prevalence, the relative risk of presenting with pneumonia 
compared to septicemia (the reference group) was higher with 
increasing age and lower for the remaining non-PCV13 sero-
types (adjusted relative risk ratio [aRRR], 0.57 [95% confidence 
interval {CI}, .49–.66]) compared to PCV13 serotypes (Table 4).
Meningitis
Meningitis was the least prevalent clinical presentation 
(1329/16 346 [8.1%]) and more common in the younger age 
groups, with children accounting for 33.0% (397/1202) and 
Table 2. Characteristics of Patients With Invasive Disease in England and Information About the Infecting Serotype, by Age Group
Characteristic
Age Group
< 2 y 2–4 y 5–14 y 15–44 y 45–64 y 65–79 y ≥ 80 y All Ages
Serotype group n = 682 n = 312 n = 253 n = 2377 n = 4728 n = 4869 n = 4229 n = 17 450
 8 61 (8.9) 15 (4.8) 27 (10.7) 720 (30.3) 1214 (25.7) 904 (18.6) 424 (10.0) 3365 (19.3)
 12F 84 (12.3) 54 (17.3) 30 (11.9) 460 (19.4) 730 (15.4) 458 (9.4) 270 (6.4) 2086 (12.0)
 9N 30 (4.4) 8 (2.6) 7 (2.8) 135 (5.7) 330 (7.0) 324 (6.7) 294 (7.0) 1128 (6.5)
 PCV13 including 3, 19A 87 (12.8) 46 (14.7) 58 (22.9) 424 (17.8) 888 (18.8) 1045 (21.5) 944 (22.3) 3492 (20.0)
  3 49 (7.2) 13 (4.2) 12 (4.7) 124 (5.2) 373 (7.9) 541 (11.1) 513 (12.1) 1625 (9.3)
  19A 20 (2.9) 22 (7.1) 14 (5.5) 119 (5.0) 250 (5.3) 276 (5.7) 245 (5.8) 946 (5.4)
 Remaining non-PCV13 serotypes 420 (61.6) 189 (60.6) 131 (51.8) 638 (26.8) 1566 (33.1) 2138 (43.9) 2297 (54.3) 7379 (42.3)
Clinical presentation n = 672 n = 295 n = 235 n = 2165 n = 4373 n = 4573 n = 4033 n = 16 346
 Meningitis 191 (28.4) 116 (39.3) 90 (38.3) 220 (10.2) 435 (10.0) 215 (4.7) 62 (1.5) 1329 (8.1)
 Pneumonia 210 (31.3) 108 (36.6) 75 (31.9) 1510 (69.8) 2957 (67.6) 3369 (73.7) 3195 (79.2) 11 424 (69.9)
 Other presentationsa 42 (6.3) 27 (9.2) 31 (13.2) 213 (9.8) 523 (12.0) 510 (11.2) 389 (9.6) 1735 (10.6)
 Bacteremia/sepsis 229 (34.1) 44 (14.9) 39 (16.6) 222 (10.3) 458 (10.5) 479 (10.5) 387 (9.6) 1858 (11.4)
At least 1 comorbidity n = 641 n = 301 n = 238 n = 2316 n = 4664 n = 4810 n = 4182 n = 17 211
 Yes 96 (15.0) 133 (44.2) 126 (52.9) 792 (34.2) 2697 (57.8) 3797 (78.9) 3392 (81.1) 11 033 (66.0)
 No 545 (85.0) 168 (55.8) 112 (47.1) 1524 (65.8) 1967 (42.2) 1013 (21.1) 790 (18.9) 5693 (34.0)
Comorbiditiesb n = 123 n = 176 n = 171 n = 1026 n = 4139 n = 7251 n = 6643 n = 19 529
 Chronic lung disease 27 (4.3) 23 (7.9) 43 (18.7) 342 (15.9) 1185 (27.0) 1904 (41.3) 1344 (33.8) 4868 (29.9)
 Chronic heart disease 35 (5.6) 22 (7.5) 9 (3.9) 42 (2.0) 460 (10.6) 1371 (29.9) 1909 (47.8) 3848 (23.7)
 Chronic renal disease 10 (1.6) 16 (5.4) 9 (3.9) 50 (2.3) 239 (5.1) 809 (17.7) 1383 (34.7) 2516 (15.5)
 Chronic liver disease 10 (1.6) 9 (3.1) 6 (2.6) 138 (6.4) 402 (9.3) 260 (5.8) 59 (1.5) 884 (5.5)
 CNS disease 5 (0.8) 6 (2.1) 10 (4.4) 47 (2.0) 113 (2.4) 138 (3.0) 141 (3.6) 460 (2.9)
 Immunosuppression/malignancy 15 (2.3) 74 (24.6) 72 (30.3) 259 (11.7) 955 (21.2) 1560 (33.3) 965 (23.6) 3900 (23.3)
 Asplenia/splenic dysfunction 11 (1.8) 8 (2.8) 7 (3.1) 18 (0.9) 38 (0.9) 29 (0.6) 12 (0.3) 123 (0.8)
 Sickle-cell disease 7 (1.2) 7 (2.5) 11 (4.9) 15 (0.7) 13 (0.3) 5 (0.1) 5 (0.1) 63 (0.4)
 Diabetes mellitus 2 (0.3) 3 (1.0) 0 (0.0) 109 (5.1) 712 (16.3) 1136 (24.8) 810 (20.5) 2772 (17.1)
 Cochlear implants 0 (0.0) 6 (2.1) 2 (0.9) 2 (0.1) 4 (0.1) 10 (0.2) 6 (0.2) 30 (0.2)
 Celiac disease 1 (0.2) 2 (0.7) 2 (0.9) 4 (0.2) 18 (0.4) 29 (0.6) 9 (0.2) 65 (0.4)
30-d case fatality rate n = 682 n = 312 n = 253 n = 2377 n = 4728 n = 4869 n = 4229 n = 17 450
29 (4.3) 15 (4.8) 10 (4.0) 93 (3.9) 494 (10.5) 799 (16.4) 1455 (34.4) 2895 (16.6)
The total number of cases with available information is indicated by “n =”; data are presented as no. of cases (% of total cases with available information).
Abbreviations: CNS, central nervous system; PCV13, 13-valent pneumococcal conjugate vaccine.
aIn children, the main other clinical presentations were septic arthritis, cellulitis, and mastoiditis; in adults, septic arthritis, cellulitis, and epiglottitis; and in older adults, biliary sepsis, 
urosepsis, and septic arthritis.
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15- to 44-year-olds accounting for 10.2% (220/1202) of pneu-
mococcal meningitis cases. The main serotypes responsible 
were 12F (186 [14.0%]), 8 (170 [12.8%]), and 3 (120 [9.0%]), 
with 43 other serotypes responsible for the remaining cases. 
Serotypes 9N (n = 73) and 19A (n = 42) were less common 
causes of pneumococcal meningitis, while serotype 7F, which 
used to be the most common cause of pneumococcal men-
ingitis prior to PCV13 introduction, contributed to 16 cases 
only (Supplementary Table 2). In the multinomial logistic re-
gression model, the relative risk of presenting with meningitis 
compared to septicemia (the reference group) was lower for 
≥ 65-year-olds, those with underlying comorbidity, and infec-
tion with serotype 8 (Table 4).
Other Presentations
Other clinical presentations included septic/osteoarthritis, cel-
lulitis, endocarditis, and urosepsis, which contributed to 10.6% 
(1735) of IPD cases across all ages (Table 2). Septicemia without 
a focus represented 11.4% (1858) of cases and was more prev-
alent in children (312/1202 [26.0%]) compared to the other 
age groups. For other clinical presentations, the risk in adult 
age groups remained at around 4–5 times higher than in chil-
dren; those with remaining non-PCV13 serotypes had 1.22-fold 
(95% CI, 1.00–1.49) higher risk of other presentations relative 
to PCV13 serotypes (Table 4).
Case Fatality Rates
There were 2895 deaths within 30 days of IPD (case fatality rate 
[CFR], 16.6% [95% CI, 16.0%–17.2%]). CFR increased with age 
from 4.3% (54/1247) in children to 34.4% (1455/4229) among 
≥ 80-year-olds (Table 2). The main serotypes contributing to death 
were 3 (434 [26.7%] of deaths), 8 (291 [10.1%]), 9N (212 [7.3%]), 
12F (209 [7.2%]), and 22F (193 [6.7%]) (Supplementary Table 2). 
Among the emerging serotypes, IPD cases due to serotype 9N was 
associated with a higher CFR (212/1128 [18.8%]) compared to se-
rotype 8 (291/3365 [8.7%]) or serotype 12F (209/2086 [10.0%]) in 
the univariate analysis (Table 3). In the logistic regression model, 
death was independently associated with increasing age, PCV13-
serotype IPD, and clinical presentation with meningitis or sep-
ticemia (relative to invasive pneumonia) (Table  5). Underlying 
comorbidity was also independently associated with a higher CFR 
(adjusted odds ratio [aOR], 1.37 [95% CI, 1.22–1.53]). When co-
morbidity status was replaced with number of comorbidities in 
the model, the risk of death increased in a stepwise manner with 
an aOR of 1.25 (95% CI, 1.10–1.41; P = .001) for 1 comorbidity, 
1.43 (95% CI, 1.25–1.63; P < .001) for 2 comorbidities, and 1.54 
(95% CI, 1.34–1.77; P  <  .001) for ≥ 3 comorbidities compared 
to those with no comorbidity. Among IPD cases with an un-
derlying comorbidity, the odds of death were not increased for 
immunocompromising conditions vs nonimmunocompromising 
conditions (aOR, 0.99 [95% CI, .89–1.09]).
Table 3. Characteristics of Invasive Pneumococcal Disease Cases in England, by Serotype Group in All Ages
Serotype Group Serotype 8 Serotype 12F Serotype 9N PCV13 Remaining All
Clinical presentation n = 3176 n = 1966 n = 1061 n = 3244 n = 6899 n = 16 346
 Meningitis 170 (5.4) 186 (9.5) 73 (6.9) 220 (6.8) 680 (9.9) 1329 (8.1)
 Pneumonia 2516 (79.2) 1330 (67.7) 788 (74.3) 2464 (76.0) 4326 (62.7) 11 424 (69.9)
 Other presentations 202 (6.4) 235 (12.0) 97 (9.1) 255 (7.9) 946 (13.7) 1735 (10.6)
 Bacteremia/sepsis 288 (9.1) 215 (10.9) 103 (9.7) 305 (9.4) 947 (13.7) 1858 (11.4)
Any comorbidity n = 3228 n = 1994 n = 1087 n = 3342 n = 7075 n = 16 726
 Yes 1901 (58.9) 1042 (52.3) 748 (68.8) 2188 (65.5) 5154 (72.8) 11 033 (66.0)
 No 1327 (41.1) 952 (47.7) 339 (31.2) 1154 (34.5) 1921 (27.2) 5693 (34.0)
Comorbiditiesa n = 3240 n = 1740 n = 1453 n = 4011 n = 9935 n = 20 379
 Chronic lung disease 1076 (34.1) 520 (26.6) 345 (32.5) 942 (29.0) 1985 (29.0) 4868 (29.9)
 Chronic heart disease 549 (17.5) 316 (16.3) 254 (24.0) 813 (25.0) 1916 (27.9) 3848 (23.7)
 Chronic renal disease 339 (10.9) 187 (9.6) 169 (16.0) 526 (16.2) 1295 (19.0) 2516 (15.5)
 Chronic liver disease 118 (3.8) 90 (4.6) 63 (6.0) 177 (5.5) 436 (6.4) 884 (5.5)
 CNS disease 66 (2.1) 39 (2.0) 40 (3.8) 87 (2.7) 228 (3.4) 460 (2.9)
 Asplenia/splenic dysfunction 6 (0.2) 10 (0.5) 5 (0.5) 9 (0.3) 93 (1.4) 123 (0.8)
 Immunosuppression/malignancy 458 (14.2) 278 (13.9) 291 (26.8) 746 (22.3) 2127 (30.0) 3900 (23.3)
 Sickle-cell disease 8 (0.3) 6 (0.3) 3 (0.3) 11 (0.3) 35 (0.5) 63 (0.4)
 Malignancy 327 (10.5) 201 (10.3) 240 (22.7) 556 (17.2) 1760 (25.7) 3084 (19.0)
 Diabetes 532 (17.0) 237 (12.2) 199 (18.9) 548 (16.9) 1256 (18.4) 2772 (17.1)
 Cochlear implants 6 (0.2) 1 (0.1) 0 (0.0) 4 (0.1) 19 (0.3) 30 (0.2)
 Celiac disease 12 (0.4) 7 (0.4) 6 (0.6) 10 (0.3) 30 (0.4) 65 (0.4)
30-d case fatality rate n = 3365 n = 2086 n = 1128 n = 3492 n = 7379 n = 17 450
291 (8.6) 209 (10.0) 212 (18.8) 737 (21.1) 1446 (19.6) 2895 (16.6)
n = denotes total number of cases with available information; data are presented as no. of cases (% of total cases with available information).
Abbreviations: CNS, central nervous system; PCV13, 13-valent pneumococcal conjugate vaccine.
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Table 4. Multinomial Logistic Regression Model With Clinical Presentation as Outcome and Reference Category as Septicemia for Cases of Invasive 
Pneumococcal Disease in England; Independent Variables in the Model Included the Surveillance Year, Age Group, Serotype Group, and Comorbidity 
Status
Clinical Presentation No. (%) aRRR (95% CI) P Value
Septicemia    
 Age group, y    
  < 15 312 (16.8) Ref  
  15–44 222 (12.0) Ref  
  45–64 458 (24.7) Ref  
  65–79 479 (25.8)   
  ≥ 80 387 (20.8) Ref  
 Comorbidity status    
  Comorbidity present 1062 (62.8) Ref  
  Healthy 630 (37.2) Ref  
 Serotype group    
  8 288 (15.5) Ref  
  12F 215 (11.6) Ref  
  9N 103 (5.5) Ref  
  PCV13 305 (16.4) Ref  
  Remaining 947 (51.0) Ref  
Meningitisa    
 Age group, y    
  < 15 397 (29.9) 1.00 (base)  
  15–44 220 (16.6) 0.97 (.75–1.25) .82
  45–64 435 (32.7) 1.01 (.81–1.25) .95
  65–79 215 (16.2) 0.50 (.39–.64) <.001
  ≥ 80 62 (4.7) 0.18 (.13–.24) <.001
 Comorbidity status    
  Comorbidity present 533 (42.1) 0.59 (.5–.7) <.001
  Healthy 734 (57.9) 1.00 (base)  
 Serotype group    
  8 170 (12.8) 0.70 (.53–.91) .008
  12F 186 (14.0) 0.89 (.68–1.18) .42
  9N 73 (5.5) 1.03 (.72–1.48) .89
  PCV13 serotypes 220 (16.6) 1.00 (base)  
  Remaining serotypes 680 (5.2) 1.03 (.84–1.28) .76
Pneumonia    
 Age group, y    
  <15 393 (3.44) 1.00 (base)  
  15–44 1510 (13.2) 5.25 (4.21–6.54) <.001
  45–64 2957 (25.9) 4.75 (3.93–5.75) <.001
  65–79 3369 (29.5) 5.23 (4.31–6.34) <.001
  ≥ 80 3195 (28.0) 6.76 (5.54–8.25) <.001
 Comorbidity status    
  Comorbidity present 7721 (69.2) 1.11 (.99–1.25) .08
  Healthy 3440 (30.8) 1.00 (base)  
 Serotype group    
  8 2516 (22.0) 1.10 (.92–1.32) .31
  12F 1330 (11.6) 0.83 (.68–1.01) .06
  9N 788 (6.9) 0.92 (.72–1.19) .54
  PCV13 serotypes 2464 (21.6) 1.00 (base)  
  Remaining serotypes 4326 (37.9) 0.57 (.49–.66) <.001
Other presentations    
 Age group, y    
  <15 100 (5.8) 1.00 (base)  
  15–44 213 (12.3) 4.19 (3.06–5.75) <.001
  45–64 523 (30.1) 4.9 (3.71–6.48) <.001
  65–79 510 (29.4) 4.38 (3.30–5.81) <.001
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Serotype 3 was associated with a higher CFR compared to 
the remaining PCV13 serotypes (434/1625 [26.7%] vs 303/1867 
[16.2%]; P < .001). Using PCV13 serotypes without serotype 3 as 
baseline in the logistic regression model, the odds of death was 
significantly higher for serotype 3 (aOR, 1.56 [95% CI, 1.30–1.86]) 
and lower for serotype 8 (aOR, 0.56 [.46–.67]) and 12F (aOR, 0.68 
[.55–.83]) as well as the remaining serotypes (aOR, 0.81 [95% CI, 
.72–.90]), but not for serotype 9N (aOR, 1.08 [95% CI, .88–1.33]).
DISCUSSION
The recently emerging serotypes causing IPD in England 
each have unique epidemiological and clinical characteristics. 
Serotypes 8 and 12F share similarities in that they cause IPD in 
younger individuals who are more likely to be healthy and less 
likely to die from their infection when compared to PCV13 sero-
types. Serotype 9N, on the other hand, behaves more like PCV13 
serotypes, and is associated with a higher comorbidity prevalence 
and CFR compared to the other 2 emerging serotypes. While 
cases due to PCV13 serotypes have declined significantly, they 
still accounted for 20% of all IPD cases. Serotype 3 IPD cases, 
in particular, have been increasing since 2013–2014, with one of 
the highest CFRs and contributing the most to total IPD deaths. 
Fifty-five other serotypes were responsible for the remaining 
42.5% of IPD cases; these serotypes were more likely to cause IPD 
in those with underlying comorbidities, and less likely to cause 
pneumonia or death when compared to PCV13-serotype IPD.
Table 5. Logistic Regression for Death Within 30 Days of an Invasive Pneumococcal Disease Episode
Variable no./No. (30-d CFR, %) Adjusted Odds Ratio (95% CI) P Value
Age group, y    
 < 15 54/1247 (4.3) 1.00 (base)  
 15–44 93/2377 (3.9) 1.05 (.73–1.51) .801
 45–64 494/4728 (10.4) 2.81 (2.07–3.81) <.001
 65–79 799/4869 (16.4) 4.33 (3.2–5.87) <.001
 ≥ 80 1455/4229 (34.4) 10.89 (8.05–14.75) <.001
Serotype group    
 8 291/3365 (8.6) 0.44 (.38–.52) <.001
 12F 209/2086 (10.0) 0.54 (.45–.64) <.001
 9N 212/1128 (18.8) 0.86 (.71–1.03) .103
 PCV13 serotypes 737/3492 (21.1) 1.00 (base)  
 Remaining serotypes 1466/7379 (19.6) 0.81 (.72–.90) <.001
Clinical presentation    
 Meningitis 145/1329 (10.9) 1.22 (1.00–1.49) .054
 Pneumonia 1974/11 424 (17.3) 1.00 (base)  
 Other presentations 293/1735 (16.9) 1.04 (.90–1.20) .636
 Septicemia 349/1858 (18.8) 1.46 (1.27–1.68) <.001
Comorbidity status    
 Healthy 560/5693 (9.8) 1.00 (base)  
 Comorbidity present 2228/11 033 (20.2) 1.37 (1.22–1.53) <.001
Dependent variables included surveillance year, age group, serotype group, clinical presentation, and comorbidity status.
Abbreviations: CFR, case fatality ratio; CI, confidence interval; PCV13, 13-valent pneumococcal conjugate vaccine.
Clinical Presentation No. (%) aRRR (95% CI) P Value
 Comorbidity status    
  Comorbidity present 1123 (66.2) 0.94 (.80–1.1) .41
  Healthy 574 (33.8) 1.00 (base)  
 Serotype group    
  8 202 (11.6) 0.80 (.62–1.03) .08
  12F 235 (13.5) 1.24 (.95–1.61) .11
  9N 97 (5.6) 1.04 (.74–1.46) .82
  PCV13 255 (14.7) 1.00 (base)  
  Remaining 946 (54.5) 1.22 (1.00–1.49) .05
Abbreviations: aRRR, adjusted relative risk ratio; CI, confidence interval; PCV13, 13-valent pneumococcal conjugate vaccine; Ref, reference group.
aExample of output interpretation for the aRRR: Meningitis cases were relatively less frequent in the oldest age groups as compared to septicemia cases, after adjusting for the other 
variables, including serotype group and comorbidity status; similarly, those with comorbidity were less likely to present with pneumococcal meningitis compared to healthy individuals. 
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Serotypes 8 and 12F share many features of highly invasive 
serotypes in that they cause invasive disease but are rarely found 
in carriage (ie, they have a high case-to-carrier ratio) [11, 12], 
affect healthy, younger individuals, and have a low CFR com-
pared to the PCV13 serotypes. Serotype 9N, on the other hand, 
was previously not present in carriage but became the ninth 
most prevalent serotype in the 2015–2016 UK carriage study, 
being isolated from < 5-year-olds, 5- to 19-year-olds, and adults 
[12]. The characteristics of this serotype, therefore, reflects other 
carried serotypes, especially non-PCV13 serotypes in that it af-
fects older individuals and those with underlying comorbidity, 
resulting in higher CFRs compared to 8 and 12F. Serotype 9N 
has persistently been associated with more severe disease and 
high case fatality [13].
Other European countries offering 10-valent PCV or 
PCV13 in their childhood immunization program have had 
differential indirect (herd) impact in adults and older adults 
after 5 years, in terms of persistence of vaccine-type IPD and 
replacement disease with nonvaccine serotypes [14]. The 
emerging serotypes have also varied in different countries, 
often without predominance of any particular serotype, al-
though some have reported higher IPD incidence due to se-
rotype 12F or 8 after higher-valent PCV implementation 
[15]. In comparison, the United States—where a 3 + 1 PCV13 
schedule has been used for almost a decade—has reported 
very little replacement disease; although some studies have re-
ported an increase in IPD due to serotypes 8 and 9N, both of 
these serotypes had only a minor contribution to overall di-
sease burden [16, 17]. There is no clear explanation for this 
disparity, although differences in sampling, population dem-
ographics,  risk factors, serotype interactions, and choice of 
vaccine schedule have been suggested to impact serotype 
replacement [16].
For the individual pneumococcal serotypes, it is difficult 
to disentangle the impact of vaccination from natural secular 
trends, especially the nonvaccine serotypes involved in replace-
ment disease. Even among the vaccine serotypes, while PCV7 
serotypes were virtually eliminated in carriage and disease after 
PCV7 introduction in the UK [18, 19], IPD due to serotypes 3 
and 19A declined during the first 4 years after PCV13 imple-
mentation [11], but subsequently serotype 19A cases plateaued 
while serotype 3 IPD cases increased to rates above pre-PCV13 
incidence [3], despite significant reductions in carriage of both 
these serotypes after PCV13 implementation [12]. These 2 sero-
types have persisted in other countries with different PCV13 
immunization schedules [20] and are, therefore, likely to re-
main in circulation even in countries with high PCV13 uptake.
In contrast to the highly invasive, less carried serotypes, those 
that are found in both carriage and disease are usually more 
predictable in terms of their propensity to cause invasive disease 
and death [21]. Reassuringly, the replacing serotypes in car-
riage after PCV13 implementation had a lower case-to-carrier 
ratio and were, therefore, less likely to cause IPD [12]. Clinical 
follow-up of cases confirms that the remaining non-PCV13 
serotypes, which are commonly carried in children, are pre-
dominantly opportunistic, causing IPD mainly in those with 
underlying comorbidity; moreover, our analysis indicates that 
while these serotypes in themselves are less likely to be fatal, 
the underlying comorbidity is independently associated with 
a significantly higher risk of death. Overall, however, the large 
contribution of serotypes 8 and 12F to total IPD burden in re-
cent years means that the overall CFR is likely to be lower now 
compared to the pre-PCV7 or the pre-PCV13 era [22].
The strength of this study is in the long-term national sur-
veillance with high case ascertainment rates and near-complete 
serotyping of invasive isolates. Extending the enhanced surveil-
lance to cover all age groups since 2014 has been challenging, 
with more than 5000 cases confirmed annually, but the high 
questionnaire return rates highlights the continued support 
provided by the primary care teams for the national immuniza-
tion program. A limitation of the study is the limited clinical in-
formation collected for IPD cases; the postal questionnaire was 
restricted to a single page to encourage high return rates for na-
tional surveillance. Another limitation is that the focus of infec-
tion relied on clinical judgement rather than strict definitions, 
such as radiological confirmation of pneumonia cases. We also 
restricted our analysis to the 3 major emerging serotypes and 
compared them to PCV13 serotypes and the remaining non-
PCV13 serotypes to demonstrate the unique characteristics of 
IPD caused by these serotypes.
CONCLUSIONS
In the UK, 3 serotypes have recently emerged as major causes 
of IPD in England, each with unique clinical and epidemiolog-
ical characteristics when compared to PCV13 serotypes and the 
remaining non-PCV13 serotypes. The low CFR associated with 
serotypes 8 and 12F IPD, which contribute to a significant pro-
portion of IPD cases, is reassuring. The remaining non-PCV13 
serotypes mainly caused opportunistic infections in those with 
underlying comorbidity. Our study highlights the importance 
of monitoring clinical disease and outcomes of individual sero-
types to better understand their contribution to the total IPD 
burden.
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